LIAISON® XL MUREX HBsAg Qual, LIAISON® MUREX Control HBsAg, and LIAISON® XL MUREX HBsAg Confirmatory Test
Test, Hepatitis B (B Antigen, B Surface Antigen, Be Antigen). PMA P190017, from DiaSorin, Inc. (Stillwater, MN). Product code LOM, class 3.
As of Nov 22, 2026, P190017 is an FDA PMA held by DiaSorin, Inc., approved on Aug 29, 2020 after 428 days, with no recalls tied to it in FDA's recall database.
- Review time: 428 days
- Supplements: 25
- Recalls: 0
- Cited as a predicate by: 1 device
Approval for the LIAISON® XL MUREX HBsAg Qual, LIAISON® MUREX Control HBsAg, and LIAISON® XL MUREX HBsAg Confirmatory Test. The LIAISON® XL MUREX HBsAg Qual assay is an in vitro chemiluminescent immunoassay for the qualitative detection of hepatitis B surface antigen (HBsAg) in human adult and pediatric (2 to 21 years) serum and plasma (lithium and sodium heparin, sodium citrate and potassium EDTA) including separator tubes, on the LIAISON® XL Analyzer. Assay results in conjunction with other hepatitis B virus (HBV) serological and clinical information, may be used as an aid in the diagnosis of HBV infection in patients with symptoms of hepatitis or who may be at risk for HBV infection. The assay may also be used to screen for HBV infection in pregnant women to identify neonates who are at risk for acquiring hepatitis B during the perinatal period.The LIAISON® XL MUREX Control HBsAg…
- Design
- Prospective and retrospective multi-site clinical agreement study vs. FDA-approved reference HBsAg assay
- Enrolled
- 3,082
- Where
- Russia, Colombia, Cameroon, Ghana, Nigeria, US
- Primary endpoint
- Positive percent agreement (PPA) and negative percent agreement (NPA) vs. FDA-approved reference HBsAg assay
- Result
- PPA 98.3% (95% CI 96.0%-99.3%); NPA 99.8% (95% CI 99.5%-99.9%)
- LIAISON Murex HBsAg Qual; LIAISON XL; LIAISON diluteXK260770 · DiaSorin, Inc. · Jun 4, 2026
| Oct 10, 2025 | S026Change Design/Components/Specifications/Material | Real-Time Process |
| Aug 28, 2025 | S028Process Change - Manufacturer/Sterilizer/Packager/Supplier | 30-Day Notice |
| Aug 21, 2025 | S027Process Change - Manufacturer/Sterilizer/Packager/Supplier | 30-Day Notice |
| Apr 25, 2025 | S023Change Design/Components/Specifications/Material | Real-Time Process |
| Apr 16, 2025 | S018Change Design/Components/Specifications/Material | Normal 180 Day Track |
| Apr 10, 2025 | S025Process Change - Manufacturer/Sterilizer/Packager/Supplier | 30-Day Notice |
| Feb 25, 2025 | S024Process Change - Manufacturer/Sterilizer/Packager/Supplier | 30-Day Notice |
| Jan 6, 2025 | S022Process Change - Manufacturer/Sterilizer/Packager/Supplier | 30-Day Notice |
| Dec 19, 2024 | S021Process Change - Manufacturer/Sterilizer/Packager/Supplier | 30-Day Notice |
| Jul 12, 2024 | S020Process Change - Manufacturer/Sterilizer/Packager/Supplier | 30-Day Notice |
| Jun 4, 2024 | S019Process Change - Manufacturer/Sterilizer/Packager/Supplier | 30-Day Notice |
| Nov 8, 2023 | S017Process Change - Manufacturer/Sterilizer/Packager/Supplier | 30-Day Notice |
| Oct 5, 2023 | S016Process Change - Manufacturer/Sterilizer/Packager/Supplier | 30-Day Notice |
| Sep 28, 2023 | S015Process Change - Manufacturer/Sterilizer/Packager/Supplier | 30-Day Notice |
| Aug 22, 2023 | S014Process Change - Manufacturer/Sterilizer/Packager/Supplier | 30-Day Notice |
- LIAISON Murex HBsAg Qual; LIAISON XL; LIAISON diluteXK260770 · DiaSorin, Inc. · Jun 4, 2026
- Document
- Approval order (PDF) ↗
- Type
- Original PMA
- Received
- Jun 28, 2019
- Review panel
- Microbiology
- Regulation
- 21 CFR 866.3172
One page per 510(k), De Novo and original PMA. Recalls are those FDA's recall database ties to this number; recalls of related devices that cite another number are not shown. Refreshed weekly. Predicates are read by Arca from the text of FDA's 510(k) summary PDFs, most of them scans: a device number counts when the summary names it as a predicate or as the device it is substantially equivalent to. About 97% of those read were right on a sample we checked by hand; summaries from before 2000 often name predicates without a number, so older devices show fewer. Pivotal studies are read by a model from FDA's De Novo decision summaries and PMA SSEDs; a count or result is shown only when its numbers appear in FDA's text. openFDA device 510(k), PMA and recall files